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Reactive oxygen species regulate redox-signaling processes, but in excess they can cause 
cell  damage,  hence  underlying  the  aetiology  of  several  neurological  diseases.  Through  its 
ability  to  down  modulate  reactive  oxygen  species,  glutathione  is  considered  an  essential 
thiol-antioxidant derivative, yet under certain circumstances it is dispensable for cell growth 
and redox control. Here we show, by directing the biosynthesis of γ-glutamylcysteine—the 
immediate  glutathione  precursor—to  mitochondria,  that  it  efficiently  detoxifies  hydrogen 
peroxide and superoxide anion, regardless of cellular glutathione concentrations. Knocking 
down glutathione peroxidase-1 drastically increases superoxide anion in cells synthesizing 
mitochondrial γ-glutamylcysteine. In vitro, γ-glutamylcysteine is as efficient as glutathione in 
disposing of hydrogen peroxide by glutathione peroxidase-1. In primary neurons, endogenously 
synthesized γ-glutamylcysteine fully prevents apoptotic death in several neurotoxic paradigms   
and, in an in vivo mouse model of neurodegeneration, γ-glutamylcysteine protects against 
neuronal loss and motor impairment. Thus, γ-glutamylcysteine takes over the antioxidant and 
neuroprotective functions of glutathione by acting as glutathione peroxidase-1 cofactor. 
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M
itochondria are both producers and targets of reactive oxy-
gen species (ROS). A well-balanced equilibrium between 
mitochondrial ROS production and their elimination is 
critical for the control of redox-mediated cell signalling processes1. 
By disposing ROS, glutathione (γ-glutamylcysteinylglycine, GSH) 
is  thought  to  be  the  main  small  thiol-antioxidant  derivative2,3. 
GSH is synthesized exclusively in the cytosol in two consecutive 
ATP-requiring steps, the first of which, and rate limiting, being 
γ-glutamylcysteine formation by glutamate-cysteine ligase (GCL); 
glutathione synthetase (GSS) then forms the tripeptide by linking 
glycine to γ-glutamylcysteine2,3. It is well documented that pharma-
cological inhibition of GCL activity4 or knockdown of the catalytic 
GCL subunit5 increases ROS abundance, which mediates cellular 
damage; GCL genetic deletion is embryonically lethal6,7.
Interestingly, GSH is dispensable for the cell growth of Saccharo-
myces cerevisiae genetically deleted of GSS8. In addition, it has been 
recently demonstrated that, in S. cerevisiase devoid of GSS, GSH is 
essential for iron–sulfur cluster assembly, but not for thiol-redox 
control9. Both in yeast8 and in human fibroblasts10, genetic GSS 
deletion results in γ-glutamylcysteine accumulation; thus the anti-
oxidant function of GSH might be adopted by γ-glutamylcysteine. 
Here  we  tested  whether—and  if  so,  how—γ-glutamylcysteine 
detoxifies hydrogen peroxide (H2O2) and superoxide anion (O2
·–) 
under intact, physiological GSH concentrations. To do so, GCL was 
directed to mitochondria, as this organelle cannot further trans-
form γ-glutamylcysteine into GSH due to the absence of GSS11. 
We found that both mitochondrial-targeted newly synthesized, and 
endogenous  γ-glutamylcysteine,  efficiently  dispose  H2O2  by  act-
ing as glutathione peroxidase-1 cofactor. These results indicate that   
γ-glutamylcysteine is an important player in cellular redox control.
Results
Targeting  functional  GCL  to  mitochondria  decreases  ROS.  To 
direct γ-glutamylcysteine synthesis to mitochondria, the full-length 
complementary DNA encoding the catalytic GCL subunit was fused 
with the mitochondrial-targeting signal of ornithine transcarbamylase. 
When expressed in HEK293T cells, this construct (mitoGCL) yielded 
a GCL protein that was confined to mitochondria and absent in the 
cytosol, as revealed by western blotting after cellular fractionation 
(Fig. 1a) and confocal microscopy (Fig. 1b). In contrast, expression 
of untagged GCL was exclusively present in the cytosol (Fig. 1a,b). 
Whole-cell  extracts  expressing  mitoGCL  revealed  a  super-shifted 
anti-GCL (1:1,000) band that was not present in the untagged GCL-
expressing cells or in the mitoGCL-transfected mitochondria (Fig. 1c), 
suggesting that only the mitochondrial-targeting epitope-processed 
form of the protein was present in the mitochondrial fraction.
Then,  we  assessed  whether  expressed  mitoGCL  yielded  func-
tional GCL within mitochondria. As shown in Fig. 1d (left panel), 
GCL activity was undetectable in mitochondria isolated from control 
cells, but present in mitoGCL-transfected cells. Furthermore, neither 
mitochondrial (Fig. 1d, middle panel) nor cytosolic (Supplementary   
Fig. S1a) GSH concentrations changed by mitoGCL expression. Inter-
estingly, H2O2 detection was significantly diminished by mitoGCL 
expression, as measured both in mitochondria (Fig. 1d, right panel) 
and in intact cells (Supplementary Fig. S1b,c). Expression of mitoGCL 
prevented the conversion of GSH to its oxidized form (GSSG) caused 
by rotenone (Supplementary Fig. S1d). To confirm that GCL activity 
wholly accounted for ROS down-modulation, we expressed (Fig. 1e) 
a E103A mutant12, inactive (Fig. 1f, left panel) form of mitoGCL. We 
found that rotenone-induced mitochondrial O2
·– was significantly 
decreased by wild-type mitoGCL, but not by the E103A inactive form 
(Fig. 1f, right panel). These data confirm that γ-glutamylcysteine is 
required for the observed antioxidant function.
-Glutamylcysteine is a GPx1 cofactor that detoxifies H2O2. To 
decipher  how  γ-glutamylcysteine  detoxified  ROS  but  otherwise 
avoiding  the  influence  of  cytosolic  GCL,  we  expressed  a  silent 
mutant mitoGCL form (mitoGCL (mut)) refractory to the action   
of a small hairpin RNA against GCL (shGCL)5, in HEK293T cells 
(Fig.  2a).  Knocking  down  GCL  markedly  reduced  total  cellular 
GSH in both mitoGCL and mitoGCL (mut) transfected cells (Supple-
mentary Fig. S1e). GCL knockdown was insufficient to trigger a   
significant increase in mitochondrial O2
·–, but this was strongly 
potentiated by rotenone and rescued by mitoGCL (mut; Fig. 2b). 
Thus,  in  unstressed  HEK293T  cells,  γ-glutamylcysteine  may  not 
contribute to the basal O2
·– regulation that can occur in primary 
neurons, in which we previously reported a significant increase in 
O2
·– by shGCL13. It therefore appears that the impact of γ-glutamyl-
cysteine as a physiological redox regulator differs among cell types. 
Next, we knocked down GSS (Fig. 2c), which resulted in endog-
enous γ-glutamylcysteine accumulation and GSH decrease (Supple-
mentary Table S1). We found that GSS knockdown abolished the 
increase in rotenone-induced O2
·–, both in the absence (Supple-
mentary Fig. S1f) and in the presence of mitoGCL (Fig. 2d).
We then sought to elucidate if γ-glutamylcysteine served as a   
glutathione peroxidase cofactor. As glutathione peroxidase-1 (GPx1) 
largely  accounts  for  mitochondrial  H2O2  detoxification14,  we 
knocked down it (Fig. 2c), which resulted in a significant enhance-
ment of rotenone-induced O2
·– (Fig. 2d). Furthermore, GSS knock-
down was unable to decrease O2
·– levels during GPx1 silencing   
(Fig. 2d). The oxidized form of γ-glutamylcysteine was undetect-
able in cultured cells (Supplementary Table S1), but it was present 
in all tissues analysed in vivo (brain, liver and kidney; Supplemen-
tary Table S2). Knocking down glutathione reductase (GSR) failed 
to enhance rotenone-induced O2
·– (Fig. 2d). To disregard a direct 
interaction of γ-glutamylcysteine with O2
·–, we silenced the mito-
chondrial isoform of superoxide dismutase (SOD2; Fig. 2c), which 
enhanced  rotenone-induced  O2
·–  (Fig.  2d).  The  ability  of  either   
γ-glutamylcysteine or its cognate cofactor, GSH, to dispose H2O2  
in vitro was then assessed in the absence or presence of purified 
GPx1. As shown in Fig. 2e, γ-glutamylcysteine and GSH were una-
ble to detoxify H2O2, unless GPx1 was present; γ-glutamylcysteine 
dose-dependently accelerated GPx1-mediated H2O2 disposal at a 
similar efficiency to that by GSH, at least at low concentrations of the 
thiols (Fig. 2e). GSR failed to improve the GPx1-dependent ability of   
γ-glutamylcysteine, but not that of GSH, at disposing H2O2 (Fig. 2f).   
We  also  tested  the  ability  of  γ-glutamylcysteine  to  induce  pro-
tein modification, which was found to be well below that of GSH   
(Supplementary Table S3).
mitoGCL decreases ROS in neurons and is neuroprotective. Neu-
rons are particularly vulnerable against excess ROS, hence requir-
ing continuous supply and regeneration of GSH for survival15. We 
therefore investigated the possible efficacy of γ-glutamylcysteine at 
detoxifying ROS in (patho) physiologically relevant neuronal death 
models. Glutamate treatment increased mitochondrial O2
·– in rat 
primary neurons (Fig. 3a; Supplementary Fig. S2a), an effect that 
was abolished by the N-methyl-d-aspartate receptor antagonist16, 
MK801 (Supplementary Fig. S2b). Expression of mitoGCL in neu-
rons was sufficient to decrease basal mitochondrial O2
·– (Fig. 3a), 
which contrasts with the lack of effect in HEK293T cells (Fig. 1f). 
The different response of these cells to mitoGCL expression is likely 
due to the above-mentioned vulnerability of neurons to oxidative 
stress15 versus the resistance of HEK293T cells (Fig. 2b). Further-
more, mitoGCL, but not its inactive E103A mutant form, prevented 
the increase in mitochondrial O2
·– induced by glutamate-receptor 
stimulation (Fig. 3a). GPx1—but not GSS or GSR—knockdown (Sup-
plementary Fig. S2c) significantly enhanced O2
·– (Fig. 3b), despite 
neurons expressed mitoGCL, indicating that GPx1 use of γ-glutamyl-
cysteine is essential for γ-glutamylcysteine-mediated O2
·– detoxifica-
tion in this model of excitotoxicity. Glutamate triggered an increase 
in the proportion of neurons with active caspase-3 (Fig. 3c) and ARTICLE     
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with annexin V + /7-AAD −  staining (Fig. 3d), indicating an intrin-
sic (mitochondrial) mode of apoptotic death; this was prevented by 
antagonizing the N-methyl-D-aspartate receptors (Supplementary 
Fig. S2d,e). Notably, mitoGCL largely—but not fully—prevented the   
rise  in  the  percentage  of  neurons  with  the  apoptotic  phenotype   
(Fig. 3c,d). In addition, mitoGCL abolished O2
·– enhancement trig-
gered  by  other  mitochondrial  ROS-inducing  agents17,18,  such  as 
rotenone, antimycin and 3-nitropropionic acid (3NP; Fig. 3e).
mitoGCL  exerts  neuroprotection  in  vivo.  To  confirm  that   
γ-glutamylcysteine exerted neuroprotection in vivo, lentiviral par-
ticles expressing wild-type or inactive (E103A) mitoGCL were ster-
eotaxically injected into the striatum of adult mice. After 3 days, 
striatal GCL activity was significantly higher in mice injected with 
mitoGCL than in those injected with inactive mitoGCL (E103A), 
whereas striatal GSH concentrations remained unchanged (Fig. 4a).   
After  3  days  of  lentiviral  injections,  mice  were  intraperitoneally 
injected with 3NP (seven doses of 50 mg kg − 1, twice daily), a well-
described model of neurodegeneration18. Indeed, we observed that 
3NP treatment induced a significant increase in neuronal apoptotic 
death in the striatum, as judged by TdT-mediated dUTP nick end 
labelling  assay,  in  the  mice  pre-injected  with  inactive  mitoGCL 
(E103A), but not in those pre-injected with wild-type mitoGCL 
(Fig. 4b,c). Notably, there was a significant loss of striatal neurons in 
the mice pre-injected with the inactive mitoGCL (E103A), but not 
in those pre-injected with the wild-type mitoGCL (Fig. 4d; Supple-
mentary Fig. S2f). Mice treated with vehicle instead of 3NP showed 
no neuronal loss, regardless of the isoform of mitoGCL (wild type or 
inactive) pre-injected (Fig. 4d; Supplementary Fig. S2f). To evaluate 
behavioural function, these mice were tested for motor coordina-
tion and balance. As shown in Fig. 4e, 3NP treatment induced a 
progressive motor impairment in the mice that were pre-injected 
with the inactive mitoGCL (E103A), but not in those pre-injected 
with the wild-type mitoGCL; mice treated with vehicle instead of 
3NP showed no motor impairment, regardless of the isoform of 
mitoGCL (wild type or inactive) pre-injected (Fig. 4e).
Discussion
Here we show that  γ-glutamylcysteine is a thiol-redox regulator 
that efficiently detoxifies mitochondrial ROS. This was evidenced 
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Figure 1 | Targeting glutamate-cysteine ligase to mitochondria decreases ROS. (a) Expression of GCL fused with the mitochondrial epitope of ornithine 
transcarbamylase (mitoGCL) in HEK293T cells shows localization in the mitochondrial, not in the cytosolic fraction, as judged by western blotting. native 
(untagged) GCL is exclusively expressed in cytosol. (b) Confocal images show co-localization of mitoGCL with the mitochondrial marker mitoDsRed, whereas 
native GCL showed typical cytosolic diffused pattern. Cells nuclei were stained with 4,6-diamidino-2-phenylindole (DAPI). scale bar, 10 µm. (c) Whole 
extracts of cells expressing mitoGCL shows both native and mitochondrial-tagged GCL, as judged by the loss of the super-shifted band in the mitochondrial 
fraction. (d) mitoGCL is functional, as judged by the presence of GCL activity (synthesis of γ-glutamylcysteine, γGC) in the mitochondrial fraction (left panel); 
mitochondrial GsH concentration was unaltered by mitoGCL expression, whereas the rate of H2o2 production(AmplexRed), after treatment with 10 µm 
rotenone, significantly decreased (right panel). (e) Expression of the wild-type (mitoGCL) and the E103A inactive mutant form of mitoGCL showed identical 
protein abundance. (f) The E103A mutant mitoGCL form is inactive (left panel), as judged by the lack of γGC formation in transfected cells; rotenone (1 µm per 
4 h) induced an increase in mitochondrial superoxide anion (o2
·–) abundance, as revealed by mitosox fluorescence detection followed by flow cytometry; this 
increase was partially prevented by the wild-type, but not by the E103A mutant inactive mitoGCL form (right panel). mitochondrial enrichment was assessed 
by VDAC (Voltage Dependent Anion Channel) immunoblotting. The cytosolic enzyme GAPDH (glyceraldehyde-3-phosphate dehydrogenase) was used to 
assess equal loading in immunoblots. nD, not detected; *P < 0.05 (analysis of variance; n = 3 independent experiments). All data are expressed as mean±s.e.m.ARTICLE
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by confining γ-glutamylcysteine synthesis to mitochondria, which 
were unable to convert the newly synthesized γ-glutamylcysteine 
into GSH due to the lack of mitochondrial GSS11. Thus, down-
modulation of mitochondrial ROS by γ-glutamylcysteine took place 
under physiological GSH concentrations. Furthermore, the robust 
antioxidant protection observed in intact GSS knockdown cells cor-
roborates such a role by endogenous γ-glutamylcysteine. Notably, 
impairing γ-glutamylcysteine biosynthesis in the cytosol, but not in 
mitochondria, still allowed γ-glutamylcysteine to efficiently detoxify 
ROS. Together, these results indicate that the antioxidant action of 
γ-glutamylcysteine takes place regardless of GSH concentrations, 
thus cannot simply rely on its ability to replenish GSH, as it can be 
seen in other paradigms19.
Our results also reveal that GPx1 is an essential component in the 
detoxifying function of γ-glutamylcysteine. Furthermore, the occur-
rence of an oxidized form of γ-glutamylcysteine in all tissues ana-
lysed, in vivo, strongly suggests the notion of a γ-glutamylcysteine 
redox cycle. However, knocking down GSR—presumably required 
for an eventual regeneration of reduced γ-glutamylcysteine from its 
oxidized form—failed to enhance O2
·–. The biochemical pathway 
responsible for the reduction of γ-glutamylcysteine from its oxi-
dized form therefore remains to be elucidated. On the other hand,   
a putative function of γ-glutamylcysteine as direct superoxide anion 
scavenger is disregarded, as SOD2 knockdown could not further 
enhance rotenone-induced O2
·–. Our data obtained by knocking 
down GPx1, both in the human HEK293T cells and in rat neurons, 
together with the in vitro experiments, strongly suggest that endog-
enous γ-glutamylcysteine is a GPx1 cofactor for H2O2 detoxifica-
tion. It cannot be ruled out that γ-glutamylcysteine could also act 
as a cofactor for other isoforms of the glutathione peroxidase fam-
ily; however, GPx1 largely accounts for most mitochondrial H2O2 
detoxification14, suggesting a major role for this isoform. Moreover, 
previous studies have shown that GPx1 can accept, albeit at a much 
lower efficiency, a range of thiol-derivatives besides GSH as the 
electron donor20. The essential cysteinyl-sulfhydryl and glutamyl-
carboxylic groups for GPx1 active site interaction and catalysis14 
are both preserved in γ-glutamylcysteine, indicating the structural 
feasibility for this function.
Due to its very low ability to synthesize and regenerate GSH,   
the brain is one of the most vulnerable tissues to excess ROS15,21. 
In Parkinson’s disease, there is an ~60% reduction in GSH concen-
tration in the substantia nigra of presymptomatic patients22, sug-
gesting  GSH  deficiency  as  one  of  the  earliest  biochemical  signs   
of this disorder. Moreover, signs of excess ROS are associated with 
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Figure 2 | -Glutamylcysteine is a GPx1 cofactor detoxifying mitochondrial H2O2. (a) Expression of an shRnA against GCL (shGCL) in HEK293T cells 
efficiently knockdowns wild-type mitoGCL, but not a mutant form of mitoGCL (mitoGCL (mut)) that is refractory to shGCL. (b) Treatment of cells  
with rotenone (1 µm; 4 h) increased mitochondrial o2
·–, as revealed by mitosox fluorescence; this was further enhanced by GCL silencing (shGCL),  
and rescued by mitoGCL (mut) expression; GCL silencing in the absence of rotenone did not significantly modify mitochondrial o2
·– in HEK293T 
cells (c) Western blots showing the efficacy of siRnA duplexes, used at 100 nm for 3 days in HEK293T cells, against glutathione synthetase (Gss), 
glutathione peroxidase-1 (GPx1), glutathione reductase (GsR) and superoxide dismutase-2 (soD2); control siRnA (siControl) was an siRnA against 
luciferase. GAPDH (glyceraldehyde-3-phosphate dehydrogenase) was used as loading control. (d) Rotenone (1 µm; 4 h) increased mitochondrial o2
·–, 
as judged by mitosox fluorescence, in mitoGCL-expressing cells; this effect was abolished by Gss silencing and enhanced by GPx1 knockdown; silencing 
Gss did not rescue the increase in o2
·– caused by GPx1 knockdown; GsR silencing did not alter, and soD2 silencing enhanced rotenone-induced Ros. 
(e) γ-Glutamylcysteine (γGC) or GsH dose-dependently disposed H2o2 in vitro, but the presence of GPx1 (0.5 u ml − 1) in the incubation medium was 
necessary for H2o2 disposal, as judged by the lack of effect of 500 µm γGC or GsH in the absence of GPx1 (w/o GPx1). (f) H2o2 disposal by GPx1 was 
not potentiated by the presence of GsR (0.5 u ml − 1) in the incubation medium when γGC (200 µm) was used (left panel); however, the presence of GsH 
(200 µm) potentiated GPx1-mediated H2o2 disposal (right panel). *P < 0.05; #P < 0.05 versus siControl (mitoGCL; analysis of variance; n = 3 independent 
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the pathophysiology of other neurodegenerative diseases, such as 
Alzheimer’s, or disorders affecting motor functional disturbances 
such as Amyotrophic Lateral Sclerosis or Huntington’s disease23. 
At the light of our data, GPx1 is essential for γ-glutamylcysteine-
mediated  ROS  detoxification  and  neuroprotection  against  dif-
ferent  insults  triggering  neurodegeneration  in  primary  neurons.   
Furthermore, we also show neuroprotection and motor improve-
ment in an in vivo mouse model of neurodegeneration18. Thus, 
targeting γ-glutamylcysteine to neuronal mitochondria represents   
an  improvement  over  the  protection  activity  of  neighbouring   
astrocytes24,25.
In conclusion, our results demonstrate that γ-glutamylcysteine 
is a thiol-redox regulator that efficiently detoxifies mitochondrial 
ROS through GPx1. In the presence of γ-glutamylcysteine taking an 
antioxidant function, GSH stops from being oxidized; moreover, the 
ability of γ-glutamylcysteine to induce protein modification is well 
below that of GSH. Thus, when γ-glutamylcysteine takes the anti-
oxidant functions, GSH utilization may be preserved for iron–sulfur   
cluster assembly and protein thiol-redox modifications, as recently 
reported9.  How  the  antioxidant  role  of  γ-glutamylcysteine  is   
regulated under (patho) physiological conditions now needs to be 
deciphered. In this context, it should be noted that, besides GCL, 
alternative  pathways  can  account  for  intracellular  γ-glutamyl-
cysteine2,3. For instance, γ-glutamyltransferase forms γ-glutamyl-
cysteine at the extracellular side of the plasma membrane and then is 
taken up by the cells through the glutamyl-amino acid transporter2. 
It would be interesting to investigate if increased γ-glutamylcysteine 
could explain the drug resistance observed in tumours associated 
with γ-glutamyltransferase overexpression26. In addition, whether 
GSH deficiency is the prime mode of the pro-oxidant actions of the 
GCL/GSS/glutamyl-amino acid transporter inhibitor, l-buthionine 
sulfoximine4 needs to be revisited. Finally, our results, showing neu-
roprotection by mitochondrial-targeted γ-glutamylcysteine biosyn-
thesis, supports the oxidative hypothesis of neurodegeneration27. 
Although classical antioxidant drugs failed in clinical trials against 
neurodegenerative disorders28, mitoGCL, by acting as a persistent 
a
+ –
– +
– –
–
–
+
+ –
– +
– –
–
–
+
* * *
*
0.0
0.5
1.0
1.5
2.0
Glutamate Untreated
Fluorescence
(arbitr
ar
y units)
Empty vector
mitoGCL
mitoGCL(E103A)
b
# #
0.0
0.5
1.0
1.5
2.0
mitoGCL
Glutamate
siControl
siControl
siGSS
siGPx1
siGPx1+siGSS
siGSR
Fluorescence
(arbitr
ar
y units)
NS
Active caspase-3 ->
c
100 101 102100 101 102
100 101 102100 101 102
mitoGCL Empty vector
GFP+ neurons
Untreated Untreated
Glutamate Glutamate
Mitochondrial O2
•–
detection in neurons
Mitochondrial O2
•–
detection in neurons
d
0
+ –
– +
+ –
– +
*
9
18
27
Empty vector
mitoGCL
Untreated
Glutamate
Apoptotic GFP
+  neurons (% )
Untreated
Empty vector
mitoGCL
0.0
0.5
1.0
1.5
2.0
e
#
#
# #
Rot AA 3NP
Fluorescence
(arbitrar
y units)
Mitochondrial O2
•–
detection in neurons
C
e
l
l
 
c
o
u
n
t
s
C
e
l
l
 
c
o
u
n
t
s
Figure 3 | mitoGCL down-modulates mitochondrial superoxide in primary neurons. (a) Transfection of rat primary neurons with mitoGCL, but not with 
its inactive form (mitoGCL (E103A)), significantly decreased basal levels of mitochondrial o2
·–, as quantified by mitosox fluorescence in the transfected 
neurons (identified by GFP +  fluorescence); mitoGCL—but not mitoGCL (mut)—fully prevented glutamate (100 µm per 5 min)-induced mitochondrial o2
·–, 
as quantified 24 h after glutamate treatment, by mitosox fluorescence. (b) silencing glutathione peroxidase-1 (siGPx1), but not glutathione synthetase 
(siGss) or glutathione reductase (siGsR), significantly enhanced glutamate (100 µm per 5 min)-mediated mitochondrial o2
·–, as judged by mitosox 
fluorescence 24 h after treatment, in mitoGCL-expressing neurons; such enhancement was not affected by Gss co-silencing. (c) Expression of mitoGCL 
rescued the increase, observed after 24 h, in active caspase-3 in GFP + -neurons triggered by glutamate (100 µm per 5 min), as assessed by flow cytometry. 
(d) mitoGCL expression prevented neuronal apoptotic death, as revealed by annexin V + /7-AAD −  neurons 24 h after glutamate treatment (100 µm per 
5 min). (e) mitoGCL expression prevented the increase in mitochondrial o2
·– (as assessed by mitosox fluorescence) caused by incubation of neurons with 
rotenone (Rot, 10 µm), antimycin A (AA, 10 µm) or 3-nitropropionic acid (3nP, 2 mm) for 15 min. ns, not significant; *P < 0.05; #P < 0.05 versus untreated  
(analysis of variance; n = 3 independent culture preparations). All data are expressed as mean±s.e.m.ARTICLE
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antioxidant source for mitochondria, may represent a new gene 
therapy strategy to improve the transient efficacy of the formers.
Methods
Plasmids and lentivirus construction. To tag the catalytic subunit of human GCL 
with a mitochondrial-targeting epitope, the 5′-end of the full-length (2,023 bp)  
cDNA-encoding GCL (GenBank accession number NM_012815) was fused  
with a cDNA fragment encoding the first 32 amino acids of human ornithine  
transcarbamylase (GenBank accession number NM_000531). The forward and  
reverse oligonucleotides of this fragment were, respectively, 5′-GATCTAT 
GCTGTTTAATCTGAGGATCCTGTTAAACAATGCAGCTTTTAGAAATGGT 
CACAACTTCATGGTTCGAAATTTTCGGTGTGGACAACCACTACAAG-3′ 
and 5′-AATTCTTGTAGTGGTTGTCCACACCGAAAATTTCGAACCAT 
GAAGTTGTGACCATTTCTAAAAGCTGCATTGTTTAACAGGATCCTCA 
GATTAAACAGCATA-3′ (BglII and EcoRI sites underlined; Thermo Scientific, 
Offenbach, Germany). The fused cDNA construct (mitoGCL) was inserted in 
pIRES2-EGFP (Invitrogen) vector and sequence-verified; mitoGCL was then sub-
cloned into pcDNA3.1 +  (Invitrogen) and pIRES2-DsRed2 (Clontech Laboratories 
Inc., Palo Alto, CA, USA) with NheI/SmaI or NheI/XmaI restriction enzymes, 
respectively. For lentiviral particles production, the full-length cDNA-encoding 
mitoGCL, or its mutant inactive E103A form, was first digested with Eco47III/SmaI 
to generate blunt ends, and then subcloned in the PmeI site of pWPI lentiviral  
vector (Didier Trono laboratory, Lausanne, Switzerland). Recombinant lentiviruses 
were generated following a standard protocol29. Viral titters were determined by 
incubation of 3T3 cells with increasing dilutions of lentivirus in the presence of 
8 µg ml − 1 polybrene (Millipore), followed by green fluorescent protein (GFP) 
quantification by flow cytometry. Lentiviral particles were re-suspended to a 
final concentration of 1.7×106 plaque formation untis (p.f.u.) per µl. To direct 
GCL expression to the cytosol, we used non-tagged GCL. To knockdown GCL by 
small hairpin RNA (shRNA), a vector-based shRNA approach using the targeting 
sequence 5′-GAAGGAGGCTACTTCTATA-3′, as we described5, was used. The 
firefly luciferase-targeted oligonucleotide 5′-CTGACGCGGAATACTTCGA-3′ 
was used as control30. The forward and reverse 64-nt-long oligonucleotides were 
annealed and inserted into the BglII/HindIII sites of pSuper-neo/GFP vector  
(OligoEngine, Seattle, WA). These constructions concomitantly express 19-bp, 
9-nucleotide stem-loop shRNAs with GFP, thus allowing the identification of 
transfected cells by fluorescence microscopy and flow cytometry.
Small interfering RNA construction. Using previously reported rational crite-
ria31,32, we designed the following target sequences to get gene expression-specific 
knockdown by short interfering RNA (siRNA). For GSS: 5′-AGGAAATTGCT 
GTGGTTTA-3′ (nucleotides 856–874 for human NM_000178) and 5′-AGA 
GAAGGAAAGAAACATA-3′ (nucleotides 713–731 for rat NM_012962). For 
GSR: 5′-AGACGAATTCCAGAATACC-3′ (nucleotides 1211–1229 for human 
NM_000637) and 5′-GGACCTGAGTTTAAACAAA-3′ (nucleotides 1154–1172 
for rat NM_053906). For glutathione peroxidase-1 (GPx1): 5′-CGCCAAGAAC 
GAAGAGATT-3′ (nucleotides 338–356 for both human, NM_00581, and rat,  
NM_030826.3). SOD2 or MnSOD: 5′-GGGAGTTGCTGGAAGCCAT-3′ (nucle-
otides 381–399 for both human, NM_000636, and rat, NM_017051). In all cases, 
TUNEL NeuN
b
Merge
mito
GCL(E103A)
+3NP
mito
GCL
+3NP
c
0
210
–
+
+
– mitoGCL
Apoptotic
neuronal death
mitoGCL(E103A)
*
*
140
70
3NP
e
3 2 1
0
100
200
300 mitoGCL(E103A)+vehicle
mitoGCL+vehicle
Days of treatment
Motor coordination
and balance
#
#
mitoGCL(E103A)+3NP
mitoGCL+3NP
L
a
t
e
n
c
y
 
t
o
 
f
a
l
l
 
(
s
)
d
0
–
+
+
–
Neuronal loss
–
+
+
–
Vehicle 3NP
1,200
800
400
N
e
u
N
+
 
c
e
l
l
s
(
e
v
e
n
t
s
 
p
e
r
 
0
.
5
 
m
m
2
)
T
U
N
E
L
+
 
/
N
e
u
N
+
 
c
e
l
l
s
(
e
v
e
n
t
s
 
p
e
r
 
0
.
3
 
m
m
2
)
mitoGCL
mitoGCL(E103A)
a
0
1
2
3
–
+
+
– mitoGCL
Striatal GCL
activity
mitoGCL(E103A)
*
γ
G
C
 
s
y
n
t
h
e
s
i
z
e
d
(
n
m
o
l
 
m
i
n
–
1
 
p
e
r
 
m
g
 
p
r
o
t
e
i
n
)
+ –
– +
Striatal GSH
concentration
0
10
20
30
nmol per mg protein
Figure 4 | mitoGCL exerts neuroprotection in vivo. (a) Lentiviral particles expressing wild-type or inactive (E103A) mitoGCL were stereotaxically injected 
(5×106 p.f.u. per 3 µl at 0.25 µl min − 1) into the striatum of adult mice. After 3 days, striatal GCL activity was significantly higher in mice injected with 
mitoGCL than in those injected with inactive mitoGCL (E103A), whereas striatal GsH concentrations remained unchanged. (b) Confocal images of striatal 
sections showing neuronal apoptotic death. After 3 days of lentiviral particles injections, 3nP was intraperitoneally injected (seven doses of 50 mg kg − 1, 
twice daily), which induced a significant increase in neuronal apoptotic death (TunEL + /neu +  cells) in the striatum, in the mice pre-injected with inactive 
mitoGCL (E103A), but not in those pre-injected with wild-type mitoGCL; scale bar, 20 µm. (c) This panel shows the quantitative data of b. (d) After 3 
days of lentiviral particles injections, 3nP was intraperitoneally injected, which induced, 3 days later, a significant loss of striatal neun +  neurons only 
in the mice that received inactive mitoGCL (E103A), but not in those that received wild-type mitoGCL; mice treated with vehicle instead of 3nP showed 
no neuronal loss regardless of the isoform of mitoGCL (wild type or inactive) lentiviral particles injected; the quantitative analysis is shown. (e) After 3 
days of lentiviral particles injections, 3nP was intraperitoneally injected, which induced, 3 days later, a progressive motor impairment (rotarod test) in 
mice pre-injected with inactive mitoGCL (E103A), but not with wild-type mitoGCL; mice treated with vehicle, instead of 3nP, showed no neuronal loss, 
regardless of the isoform of mitoGCL (wild type or inactive) pre-injected. *P < 0.05; #P < 0.05 versus all conditions on each day (student’s t-test for (a,c); 
n = 3 mice; analysis of variance for (d,e); n = 6–8 mice). TunEL, TdT-mediated duTP nick end labelling. All data are expressed as mean±s.e.m.ARTICLE     

nATuRE CommunICATIons | DoI: 10.1038/ncomms1722
nATuRE CommunICATIons | 3:718 | DoI: 10.1038/ncomms1722 | www.nature.com/naturecommunications
© 2012 Macmillan Publishers Limited. All rights reserved.
a siRNA against luciferase (5′-CTGACGCGGAATACTTCGATT-3′) was used 
as control. siRNAs were purchased from Dharmacon (Abgene, Thermo Fisher, 
Epsom, UK).
Site-directed mutagenesis. Mutant forms of mitoGCL refractory to the shRNA 
against GCL (mitoGCLmut) or catalytically inactive mitoGCL (mitoGCL (E103A)) 
were generated using the site-directed mutagenesis QuikChange XL kit (Stratagene, 
La Jolla, CA, USA), followed by DpnI digestion. The forward and reverse oligo-
nucleotides of the sequence 5′-GAAAGAAGCCACGTCAGTT-3′, carrying silent 
third-codon base point mutations (mutant nucleotides underlined) were used for 
mitoGCLmut. To generate mitoGCL (E103A), the forward and reverse oligonucle-
otides 5′-CAGAGTATGGGAGTTACATGATTGCAGGGACACCTGGCCA 
GCCGTACGGA-3′ (mutant nucleotides underlined) were used.
Cell cultures. Cortical neurons in primary culture were prepared from fetal Wistar 
rats (E16), seeded at 2.5×105 cells per cm2 in 6- or 12-well plates previously coated 
with poly-D-lysine (15 µg ml − 1) in DMEM (Sigma, Madrid, Spain) supplemented 
with 10% (v/v) fetal calf serum (Roche Diagnostics, Heidelberg, Germany). Cells 
were incubated at 37 °C in a humidified 5% CO2-containing atmosphere. At 48 h 
after plating, the medium was replaced with DMEM supplemented with 5% horse 
serum (Sigma), 20 mM d-glucose and, on day 4, cytosine arabinoside (10 µM) to 
prevent non-neuronal proliferation33. Human embryonic kidney 293T (HEK293T) 
cells were maintained in DMEM supplemented with 10% (v/v) fetal calf serum. 
Cell transfections and treatments are specified in the Supplementary Methods. 
Cytosol was fractionated from mitochondria by differential centrifugation34.
Primary antibodies for western blotting. Immunoblotting was performed with 
rabbit polyclonal anti-GCL (1:1,000)5, rabbit polyclonal anti-GPX1 (1:1,000) 
(ab59546, Abcam, Cambridge, UK), rabbit polyclonal anti-GFP (1:1,000) (ab290, 
Abcam), mouse monoclonal anti-GSS (1:1,000) (Sc-166882, Santa Cruz Biotech-
nologies, Heidelberg, Germany), mouse monoclonal anti-GSR (Sc-133159, Santa 
Cruz Biotechnologies), mouse monoclonal anti-SOD2 (1:2,000) (ab16,956, Abcam),   
rabbit polyclonal anti-VDAC (1:1,000) (Calbiochem, Darmstadt, Germany) or 
mouse monoclonal anti-GAPDH (1:40,000) (glyceraldehyde-3-phosphate dehydro-
genase; Ambion, Cambridge, UK) antibodies. VDAC and GAPDH were used  
as mitochondrial and cytosolic (or whole cell) loading controls, respectively.
Determination of ROS. Mitochondrial superoxide was detected using the fluores-
cent MitoSox probe (Invitrogen). Cells were incubated in Hank’s buffer with 2 µM 
MitoSox-Red for 30 min at 37 °C in a 5% CO2 atmosphere, washed with PBS and 
the fluorescence assessed by flow cytometry or fluorescence microscopy. We used 
the FL1, FL2 and FL3 channels of a FACScalibur flow cytometer (15 mW argon  
ion laser tuned at 488 nm; CellQuest software, Becton Dickinson Biosciences). 
Thresholds were adjusted by using non-stained and stained cells for MitoSOX  
fluorescence, and transfected and non-transfected cells for GFP fluorescence. 
For H2O2 assessment in isolated mitochondria, 50 µg protein-aliquots of freshly 
obtained mitochondria were incubated with 100 µM AmplexRed probe (Invit-
rogen) in mitochondrial respiration buffer (125 mM KCl, 2 mM KH2PO4, 1 mM 
MgCl2, 0.5 mg ml − 1 bovine serum albumin and 10 mM HEPES, pH 7.4) contain-
ing horseradish peroxidase (0.5 U ml − 1). Luminescence was recorded for 45 min 
at 1 min intervals using a Fluoroskan Ascent FL (Thermo Scientific, Rockford, IL, 
USA) fluorimeter (excitation: 538 nm, emission: 604 nm), and the slopes were used 
for calculations. For H2O2 assessment in whole cell, 1.5×104 cells were incubated 
in 100 µM AmplexRed in Krebs-Ringer Phosphate buffer (145 mM NaCl, 5.7 mM 
Na2PO4, 4.86 mM KCl, 0.54 mM CaCl2, 1.22 mM MgSO4 and 5.5 mM glucose,  
pH 7.4), and the luminescence recorded as we did for mitochondria. Mitochon-
drial H2O2 was also detected by fluorescence microscopy in seeded, intact cells 
following the green fluorescence emitted by cells transfected with pHyPer-dMito 
plasmid vector (Evrogen, Moscow, Russia), which express a mitochondrial-tagged 
H2O2-sensitive fluorescent probe. In vitro H2O2 quantification was assessed as 
indicated in the Supplementary Methods.
Determination of -glutamylcysteine level and GCL activity. This was 
performed as described35. Cells were washed, colleted with 1 mM EDTA in 
PBS, pelleted (500g for 5 min) and re-suspended in isolation medium (320 mM 
sucrose, 10 mM Tris–HCl, 1 mM EDTA, pH 7.4). Samples (whole cells or isolated 
mitochondria) were freeze-thawed three times, and the lysates filtered through 
10-kDa molecular mass cutoff devices (Amicon, Millipore) at 12,000g for 15 min 
at 4 °C. The retained protein fraction was immediately used for the determination 
of γ-glutamylcysteine concentration or assayed for GCL activity in 0.1 M Tris–HCl 
buffer containing 0.15 mM KCl, 20 mM MgCl2, 2 mM EDTA, 10 mM ATP, 10 mM 
L-cysteine, 40 mM l-glutamate and 220 µM acivicin, pH 8.2, at 37 °C for 15 min. 
The reaction was stopped by addition of ice-cold orthophosphoric acid (15 mM,  
final concentration), and the reaction product was immediately used for γ-
glutamylcysteine determination. This was performed by high-pressure liquid chro-
matography using a LC-20A Shimadzu equipment (Shimadzu GmbH, Duisburg) 
with an interphase module (CBM-20A, Shimadzu GmbH) and electrochemical 
detection (ESA Biosciences, Inc., Chelmsford, MA), with the upstream electrode 
set at  + 100 mV (for compounds with low oxidation potential) and downstream 
electrode set between  + 100 and  + 650 mV (in  + 50 mV increments) for each 
injected standard to determine the optimum potential for detection. The samples 
were subjected to analysis with a Teknokroma MediterraneaSea18 ODS column 
(4.6×250 mm, 5-µm particle size), using 15 mM orthophosphoric acid as the 
mobile phase35 at a flow rate of 0.5 ml min − 1. An external standard of 2.5–10 µM 
γ-glutamylcysteine (Bachem, Germany) was used for the calculations. In prelimi-
nary experiments, we tested that γ-glutamylcysteine synthesis was linear with the 
incubation time at least up to 20 min. Glutathione and other thiols, disulphides, 
and protein disulphides formed with low-molecular-weight thiols were assayed 
by ultra performance liquid chromatography and mass spectrometric detection as 
described in Supplementary Methods.
Protein determinations. Cells or tissues were lysed in 0.1 M NaOH and used for 
the determination of protein concentrations, either by the method of Lowry et al., 
as described36 or by the BCA protein assay kit (Pierce), following the manufactur-
er’s instructions. In both cases, bovine serum albumin was used as standard.
Statistical analysis. All measurements in cell culture were carried out, at least, 
in triplicate, and the results are expressed as the mean ± s.e.m. values from at least 
three different culture preparations. For the rotarod experiments, we used six to 
eight animals per condition. Statistical analysis of the results was performed by 
one-way analysis of variance, followed by the least significant difference multiple 
range test or by the Student’s t-test for comparisons between two groups of values. 
In all cases, P < 0.05 was considered significant.
Use of animals. All animals used in this wok were obtained from the Animal 
Experimentation Unit of the University of Salamanca, in accordance with Spanish 
legislation (RD 1201/2005) under licence from the Spanish Ministry of Science and 
Innovation. Protocols were approved by the Bioethics Committee of the University 
of Salamanca. 
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